Company / Total Assets
Inhibrx Biosciences, Inc. Total Assets History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$146.5M
FY2025
5-year range
$146.5M / $307.9M
FY2023-FY2025
Trend
-19.0%
vs FY2024
Sector context
#205 of 214
Health Care
What the data says
Among 214 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 4% for total assets. Declined from $308M to $146M over the past 2 years.
Based on SEC 10-K filings.
$146M in FY2025.
Declined from $308M to $146M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 214This company $146.5M Sector average $7.5B
▼
-98.0% below sector average
Key checks
Key Insights
- In FY2025, total assets decreased 19.0% year-over-year.
- Ranks #205 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $146.5M | -19.0% |
| FY2024 | $180.8M | -41.3% |
| FY2023 | $307.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026